In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The author has completed the ICMJE form and declares the following conflicts of interest: She is a research assistant and principal investigator at a fetal medicine centre involved in the nipocalimab ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational ...

Johnson & Johnson (NYSE:JNJ), a global healthcare leader, finds itself at a pivotal juncture as it navigates a landscape of ...

There have been great advances in the field of generalised myasthenia gravis (gMG) in recent years, but many patients remain dissatisfied with their disease state despite being on treatment. There is ...